Jefferies Reinstates Buy on Amphastar Pharma, Announces $70 Price Target
Portfolio Pulse from richadhand@benzinga.com
Jefferies analyst Glen Santangelo has reinstated Amphastar Pharma (NASDAQ:AMPH) with a Buy rating and announced a $70 price target.
July 25, 2023 | 2:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Amphastar Pharma has been reinstated with a Buy rating by Jefferies, with a price target of $70.
The reinstatement of a Buy rating by Jefferies, along with a significant price target of $70, indicates a positive outlook for Amphastar Pharma. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100